Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

Masahiro Shinoda, Hirotoshi Ebinuma, Osamu Itano, Yoshiyuki Yamagishi, Hideaki Obara, Minoru Kitago, Nobuhiro Nakamoto, Taizo Hibi, Hiroshi Yagi, Yuta Abe, Kentaro Matsubara, Po sung Chu, Yuko Wakayama, Nobuhito Taniki, Akihiro Yamaguchi, Ryusuke Amemiya, Rei Miyake, Takamasa Mizota, Takanori Kanai, Yuko Kitagawa

研究成果: Article査読

3 被引用数 (Scopus)

抄録

Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.

本文言語English
ページ(範囲)1118-1128
ページ数11
ジャーナルHepatology Research
46
11
DOI
出版ステータスPublished - 2016 10 1

ASJC Scopus subject areas

  • 肝臓学
  • 感染症

フィンガープリント

「Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル